NEWSROOM

Press releases

Meissa Vaccines Enters into cGMP Manufacturing Agreement for Pediatric RSV Vaccine Candidate for Phase 2 Clinical Trials

November 28, 2023

Exothera’s CTO Patrick Thiaville nominated as a member of Alliance for mRNA Medicines Board

Read the press release

Meissa Vaccines Enters into cGMP Manufacturing Agreement for Pediatric RSV Vaccine Candidate for Phase 2 Clinical Trials

August 16, 2023

NIH and Exothera collaborate to produce GMP intranasal vaccine against SARS-CoV-2 for clinical phase I/II trial in Africa and US

Read the press release

Meissa Vaccines Enters into cGMP Manufacturing Agreement for Pediatric RSV Vaccine Candidate for Phase 2 Clinical Trials

June 28, 2023

Meissa Vaccines Enters into cGMP Manufacturing Agreement for Pediatric RSV Vaccine Candidate for Phase 2 Clinical Trials

Read the press release

Exothera Nucleic Acids Strengthens Team with Industry Expert Patrick Thiaville

May 9, 2023

Exothera Nucleic Acids Strengthens Team with Industry Expert 

Read the press release

Exothera announces new business unit for the development and production of RNA

April 19, 2023

Exothera announces a strategic partnership with Quantoom Biosciences and launches a new business unit for the development and production of RNA

Read the press release

Remedium and Exothera partner for AAV2-FGF18

March 22, 2023

Remedium and Exothera partner on scale-up and demonstration runs for AAV2-FGF18

Read the press release

Darren Leva CBO at Exothera announced

February 1, 2023

Exothera announces the appointment of Darren Leva as Chief Business Officer

Read the press release

Vallo Therapeutics and Exothera collaboration

January 11, 2023

Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing

Read the press release

Vaccizone and Exothera collaboration Sars-Cov-2

July 6, 2022

Vaccizone selects Exothera for process development and GMP manufacturing of its SARS‑CoV‑2 vaccine based on proprietary ASC technology

Read the press release

PAT4CGT initiative Exothera involved

June 16, 2022

PAT4CGT Consortium Announces Prestigious €4.7M Pathfinder Grant Awarded by European Innovation Council for the Development of Modular Cell & Gene Therapy Manufacturing Platform

Read the press release

Industrial scale AAV press release with LogicBio and Polyplus

June 15, 2022

Exothera announces industrial scale AAV manufacturing collaboration with LogicBio Therapeutics and Polyplus

Read the press release

press release ready-to-use viral vector production platform, exoREADY

June 9, 2022

Exothera develops exoREADY, a ready-to-use viral vector production platform, to accelerate advanced therapy manufacture at scale 

Read the press release

ReiThera and Exothera Collaborate to Develop Large-scale, Low Cost per Dose Manufacturing Process to Deliver Novel Vaccines to Low- and Middle-Income Countries

April 12, 2022

ReiThera and Exothera Collaborate to Develop Large-scale, Low Cost per Dose Manufacturing Process to Deliver Novel Vaccines to Low- and Middle-Income Countries

Read the press release

Rokote Laboratories slects Exothera for GMP manufacturing of coronavirus vaccine FINCoVac 2.0.

March 31, 2022

Rokote Laboratories selects Exothera for GMP manufacturing of its second-generation coronavirus vaccine FINCoVac 2.0.

Read the press release

GMP facilities Jumet announcement

March 23, 2022

GMP certification for Exothera further expands its viral vector manufacturing capacity

Read the press release

IDT biologika and Exothera to push forward viral vaccine scale up

March 1, 2022

IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines

Read the press release

Hanna Lesch new CTO of Exothera viral vectors

October 27, 2021

Exothera announces the appointment of Hanna Lesch as Chief Technology Officer

Read the press release

GeneQuine and Exothera for osteoarthritis gene therapy development

September 9, 2021

GeneQuine selects Exothera to support the next stage of its osteoarthritis gene therapy development

Read the press release

Pall Corporation Contract With Exothera

July 1, 2021

Pall Corporation Secures Multi-Million Dollar Contract With Exothera

Read the press release

Thibault Jonckheere as new CEO of Exothera

June 1, 2021

Univercells and Exothera announce Thibault Jonckheere as the  new CEO of Exothera

Read the press release

Codagenix and Univercells Collaboration High-Priority Human Vaccine Target

May 20, 2021

Codagenix and Univercells Announce Research Collaboration on Undisclosed, High-Priority Human Vaccine Target with Global Public Health Demand

Read the press release

March 24, 2021

CyanVac selects Exothera for the development and GMP manufacturing of its COVID-19 intranasal vaccine candidate for phase III clinical trial in Europe and the US

Read the press release

Exothera completes state-of-the-art technologies by acquiring the new generation of the NevoLine™ Upstream platform for its new site in Belgium

January 28, 2021

Exothera completes its range of state-of-the-art technologies by acquiring the new generation of the NevoLine™ Upstream platform for its new site in Belgium

Read the press release

Univercells launches cell & gene therapy CDMO Exothera with GMP capabilities

March 19, 2020

Univercells launches cell & gene therapy contract development and manufacturing organization (CDMO) Exothera with GMP capabilities in 15,000m² site in Jumet, Belgium

Read the press release